| [1] |
Howarth DM, Gilchrist GS, Mullan BP, et al.
Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome[J]. CancerCancer, 1999, 85(10): 2278-2290.
doi: 10.1002/(sici)1097-0142(19990515)85:10<2278::aid-cncr25>3.0.co;2-u |
| [2] |
Gadner H, Minkov M, Grois N, et al.
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis[J]. BloodBlood, 2013, 121(25): 5006-5014.
doi: 10.1182/blood-2012-09-455774 |
| [3] |
Monsereenusorn C, Rodriguez-Galindo C.
Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis[J]. Hematol Oncol Clin North AmHematol Oncol Clin North Am, 2015, 29(5): 853-873.
doi: 10.1016/j.hoc.2015.06.005 |
| [4] |
Chaudhary V, Bano S, Aggarwal R, et al.
Neuroimaging of Langerhans cell histiocytosis: a radiological review[J]. Jpn J RadiolJpn J Radiol, 2013, 31(12): 786-796.
doi: 10.1007/s11604-013-0254-0 |
| [5] |
Jessop S, Crudgington D, London K, et al. FDG PET-CT in pediatric Langerhans cell histiocytosis[J/OL]. Pediatr Blood Cancer, 2020, 67(1): e28034[2020-01-19]. https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.28034. DOI: 10.1002/pbc.28034. |
| [6] |
Albano D, Bosio G, Giubbini R, et al.
Role of 18F-FDG PET/CT in patients affected by Langerhans cell histiocytosis[J]. Jpn J RadiolJpn J Radiol, 2017, 35(10): 574-583.
doi: 10.1007/s11604-017-0668-1 |
| [7] |
Obert J, Vercellino L, Van Der Gucht A, et al.
18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2017, 44(4): 598-610.
doi: 10.1007/s00259-016-3521-3 |